Effects of daily versus weekly teriparatide for medication‐related osteonecrosis of the jaw: A case–control study
Oral Diseases · 2024-07 · 30 (5) · 3286-3295
DOI: 10.1111/odi.14801 ↗At a glance
Journal article in Oral Diseases, published online on 2023-11-05. Written by Kang-Min Kim and 7 co-authors. Institution: Department of Oral and Maxillofacial Surgery, College of Medicine, Ewha Womans University, Seoul, South Korea. Major MEDLINE topics: Teriparatide, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents. Cited 19 times so far (Crossref); 24 references. Funded by: Korea Health Industry Development Institute, National Research Foundation of Korea.
Abstract (original language)
Introduction
Medication‐related osteonecrosis of the jaw (MRONJ) is uncommon but can result in severe destruction of the jaw. This case–control study investigated the therapeutic effects of daily or weekly administration of teriparatide in the management of MRONJ using a cohort for osteonecrosis of the jaw.
Methods
Patients who were diagnosed with MRONJ and consented to teriparatide administration were assigned either to a group of daily injection or of weekly injection and completed a 4‐week course of injection preoperatively and at least an 8‐week course postoperatively. The control group received either the intraoperative rhBMP treatment (CG_BMP) or no additional perioperative treatment (CG_noBMP). The state of MRONJ was evaluated 2 months (T1) and 6 months (T2) postoperatively for all participants.
Results
Either group of daily injection (8.35 weeks ± 1.58; n = 17) or weekly injection (9.17 ± 3.79; n = 12) showed significantly faster healing than those of CG_BMP (14.40 ± 6.08; n = 25) or CG_noBMP (15.79 ± 9.79; n = 39). MRONJ was resolved completely in 24 out of 29 participants who completed the course of teriparatide injections, whereas 46.9% of CG showed delayed resolution. Multiple regression analysis indicated 7.50 times (95% CI, 1.77–31.82) more likelihood of complete resolution of MRONJ for participants with teriparatide injections.
Conclusion
A course of daily or weekly administration of teriparatide injections may improve treatment outcomes for patients with MRONJ.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Oral and Maxillofacial Surgery, College of Medicine, Ewha Womans University, Seoul, South Korea.
- Project for Korean National Cohort for Osteonecrosis of the Jaw.
- Graduate School of Clinical Dentistry, Ewha Womans University, Seoul, South Korea.
- Graduate School of Medicine, Ewha Womans University, Seoul, South Korea.
- Department of Conservative Dentistry, Yonsei University College of Dentistry, Seoul, South Korea.
- Department of Surgery, Division of Plastic and Reconstructive Surgery, Maxillofacial and Airway Orthodontics, School of Medicine, Stanford University, Palo Alto, California, USA.
ORCID profiles: Jung-Hyun Park, Jin-Woo Kim
Funding
- Korea Health Industry Development Institute
- National Research Foundation of Korea
Cite
APA
Kim, K. M., Kim, S., Hwang, H., Kim, H. Y., Kim, D., Park, J. H., Choo, H., & Kim, J. W. (2024). Effects of daily versus weekly teriparatide for medication‐related osteonecrosis of the jaw: A case–control study. Oral Diseases, 30(5), 3286-3295. https://doi.org/10.1111/odi.14801
Vancouver
Kim KM, Kim S, Hwang H, Kim HY, Kim D, Park JH, et al. Effects of daily versus weekly teriparatide for medication‐related osteonecrosis of the jaw: A case–control study. Oral Diseases. 2024;30(5):3286-3295. doi:10.1111/odi.14801
BibTeX
@article{Kim2024,
author = {Kim, Kang-Min and Kim, Sehyang and Hwang, Hyun and Kim, Hey-Yun and Kim, Dohyun and Park, Jung-Hyun and Choo, HyeRan and Kim, Jin-Woo},
title = {Effects of daily versus weekly teriparatide for medication‐related osteonecrosis of the jaw: A case–control study},
journal = {Oral Diseases},
year = {2024},
volume = {30},
number = {5},
pages = {3286--3295},
doi = {10.1111/odi.14801}
}
EUVIMED